Mark For: XENBEXUS™ trademark registration is intended to cover the categories of pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, antifungal preparations, antivirals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer and cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy and T Cell therapy use; Pharmaceutical preparations for human use, namely, stem cells for medical and medical clinic purposes. [all]
Status
2021-07-02 UTC
LIVE APPLICATION Published for Opposition
A pending trademark application has been examined by the Office and has been published in a way that provides an opportunity for the public to oppose its registration.
(Pharmaceuticals) Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
Filed Use
No
Current Use
No
Intent To Use
Yes
Filed ITU
Yes
44D Filed
No
44E Current
No
66A Current
No
Current Basis
No
No Basis
No
Attorney Name
Xiomara Triana
Attorney Docket Number
00138714-US
Timeline
2020-02-18
Application Filed
2020-02-21
Location: NEW APPLICATION PROCESSING
2020-02-21
Status: Live/Pending
2020-02-21
Transaction Date
2021-04-27
Location: PUBLICATION AND ISSUE SECTION
2021-06-01
Published
2021-06-01
Status: Application has been published for opposition. The opposition period begins on the date of publication.
IC 005. US 005 006 018 044 046 051 052. G & S: Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, antifungal preparations, antivirals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer and cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy and T Cell therapy use; Pharmaceutical preparations for human use, namely, stem cells for medical and medical clinic purposes
International Codes:
5
U.S. Codes:
006,018,044,046,051,052
Type Code
Type
GS0051
Pharmaceutical preparations for human use
Trademark Filing History
Description
Date
Proceeding Number
PUBLISHED FOR OPPOSITION
2021-06-01
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
2021-06-01
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
2021-05-12
APPROVED FOR PUB - PRINCIPAL REGISTER
2021-04-26
TEAS/EMAIL CORRESPONDENCE ENTERED
2021-04-24
88889
TEAS REQUEST FOR RECONSIDERATION RECEIVED
2021-04-23
CORRESPONDENCE RECEIVED IN LAW OFFICE
2021-04-23
88889
NOTIFICATION OF FINAL REFUSAL EMAILED
2020-10-23
FINAL REFUSAL WRITTEN
2020-10-23
93055
FINAL REFUSAL E-MAILED
2020-10-23
TEAS/EMAIL CORRESPONDENCE ENTERED
2020-09-29
88889
TEAS RESPONSE TO OFFICE ACTION RECEIVED
2020-09-28
CORRESPONDENCE RECEIVED IN LAW OFFICE
2020-09-28
88889
NOTIFICATION OF NON-FINAL ACTION E-MAILED
2020-03-30
6325
NON-FINAL ACTION WRITTEN
2020-03-30
93055
NON-FINAL ACTION E-MAILED
2020-03-30
6325
ASSIGNED TO EXAMINER
2020-03-29
93055
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
2020-02-22
NEW APPLICATION ENTERED IN TRAM
2020-02-21
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
OneLook
Acronym Finder
Celgene Corporation
Application
Drawing
| 